Clinical trials: Affective Disorder
Major Depression, Dysthymia
Treating Depression Among Low-Income Patients With Cancer
The ADAPt-C collaborative depression care model is designed to: improve depression symptom reduction in the intervention group over the modestly enhanced usual care group of low-income, predominantly Hispanic, patients with…
- Trial name
- ADAPt-C (NCT00565110)
- Testing
- ADAPt-C intervention
- Where
- United States
- Volunteers
- 472 people
- Sponsor
- University of Southern California
Insomnia, Major Depressive Disorder
The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy
The purpose of this study is to investigate exploratorily the effect of ramelteon 8 mg once daily for 8 weeks in the treatment of insomnia patients with depression by using actigraphy.
- Trial name
- NCT02669082
- Testing
- Ramelteon
- Where
- 7 sites in Japan
- Volunteers
- 26 people
- Sponsor
- Takeda
Major Depression in Remission
Feasibility of Adherence to Light Therapy
In this feasibility study, we propose an important question: What factors will affect participant adherence to the daily use of light therapy for maintenance treatment of depression? To answer this question, we will conduct a…
- Trial name
- NCT04944758
- Testing
- Light therapy
- Where
- Canada
- Volunteers
- 1 people
- Sponsor
- University of British Columbia
Major Depressive Disorder
Venlafaxine ER Phase 3 Study for Major Depressive Disorder (MDD)
This is a phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of venlafaxine ER 75 mg/day (fixed dose) and venlafaxine ER 75 mg/day to 225 mg/day (flexible…
- Trial name
- NCT01441440
- Testing
- venlafaxine ER 75 mg/day (fixed dose), venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)
- Where
- 63 sites in Japan
- Volunteers
- 538 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Mild Cognitive Impairment, Major Depressive Disorder
Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment
Alzheimer's disease (AD), the most common dementing disorder of later life, is a major cause of disability and death in the elderly. Although a number of theoretical causes exist, the etiology of AD is still unknown.
- Conditions
- Mild Cognitive Impairment, Major Depressive Disorder, Alzheimer's Disease
- Trial name
- NCT01876823
- Testing
- es-citalopram, Memantine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- New York State Psychiatric Institute
Depression, Major Depressive Disorder
Flavanol Augmentation for Antidepressant Non-Responsive Late Life Depression
The goal of this proposal is to conduct the first pilot study of whether consuming flavanol supplements will augment the cognitive and mood benefits of antidepressant medication in older adults with Late LifeDepression (LLD).
- Trial name
- Flavanol (NCT02943096)
- Testing
- CocoaVia
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- New York State Psychiatric Institute
Bipolar Disorder
A Double-Blind Placebo Controlled Trial of Riluzole in Bipolar Depression
The Johns Hopkins Department of Psychiatry is conducting a research study to examine the effectiveness of riluzole in treating the depressed phase of bipolar disorder.
- Trial name
- NCT00376220
- Testing
- Riluzole
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Johns Hopkins University
Opioid Use Disorder, Severe, in Sustained Remission, Opioid Use Disorder, Severe, in Early Remission
KAP for Depression in Abstinent Opioid Users
The purpose of the study is to examine whether an investigational medication called ketamine along with psychotherapy is an effective treatment for depression in participants with a history of opioid addiction who have not abused…
- Conditions
- Opioid Use Disorder, Severe, in Sustained Remission, Opioid Use Disorder, Severe, in Early Remission, Major Depressive Disorder
- Trial name
- KReDO (NCT05193318)
- Testing
- Ketamine-assisted psychotherapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Medical University of South Carolina
Major Depressive Disorder
Stress and the Sympathetic Nervous System in Adults With Depression
To test our hypotheses, we will enroll healthy adults having no history of mood disorders and adults with major depressive disorder (MDD) having a broad range of depressive symptom severity.
- Trial name
- NCT04838262
- Testing
- Acute Stressors
- Where
- United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- University of Delaware
Treatment Resistant Depression, Electroconvulsive Therapy
ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)
The goal of the study is to conduct a comparative randomized trial of electroconvulsive therapy (ECT) vs. ketamine for patients with treatment resistant depression (TRD) in a real world setting with patient reported outcomes as…
- Conditions
- Treatment Resistant Depression, Electroconvulsive Therapy, ECT, Ketamine
- Trial name
- ELEKT-D (NCT03113968)
- Testing
- electroconvulsive therapy (ECT), Ketamine
- Where
- 5 sites in United States
- Volunteers
- 403 people
- Sponsor
- Bo Hu
Emotional Disturbances, Depression
Healthy Lifestyle Intervention for High-Risk Minority Pregnant Women
The overall purpose of this application is to evaluate the efficacy of an intervention designed to decrease health disparities in pregnant, emotionally distressed, minority women.
- Conditions
- Emotional Disturbances, Depression, Pregnancy Late, Post-Partum Depression
- Trial name
- A-RCT (NCT03416010)
- Testing
- COPE-P
- Where
- 3 sites in United States
- Volunteers
- 299 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Schizophrenia, Bipolar Disorder
Lurasidone Extended Use Study
This is an open-label continuation study designed to monitor the safety, tolerability and effectiveness of lurasidone in subjects who have completed participation in a lurasidone extension study (NCT00868959 and NCT01566162) and…
- Trial name
- NCT01485640
- Testing
- Lurasidone
- Where
- 46 sites in Canada, Colombia and 10 more
- Volunteers
- 162 people
- Sponsor
- Sumitomo Pharma America, Inc.
Bipolar Disorder
Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania
This is a study designed to evaluate the efficacy, safety, and tolerability of RGH-188 monotherapy in the treatment of acute mania.
- Trial name
- NCT00488618
- Testing
- Cariprazine (RGH-188)
- Where
- United States
- Volunteers
- 238 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Improving Therapeutic Learning in Depression: Proof of Concept
Despite advances in both pharmacotherapy and psychotherapy for major depression, non-response and partial-response remain relatively common outcomes, motivating the search for new treatments.
- Trial name
- NCT02376257
- Testing
- 250 mg DCS, 100 mg Modafinil
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Boston University Charles River Campus
Treatment Resistant Depression, Major Depressive Disorder
Optimizing Outcomes of Treatment-Resistant Depression in Older Adults
The purpose of this research study is to assess which antidepressants work the best in older adults who have treatment-resistant depression (TRD).
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression
- Trial name
- OPTIMUM (NCT02960763)
- Testing
- Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion
- Where
- 5 sites in United States, Canada
- Volunteers
- 742 people
- Sponsor
- Washington University School of Medicine
Major Depressive Disorder
Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder
This proposed study sets out to examine the antidepressant effects of tocilizumab among patients with treatment-refractory major depression.
- Trial name
- NCT02660528
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Brigham and Women's Hospital
Major Depression, Generalized Anxiety Disorder
Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines
The hypothesis of this study is that symptoms of anxiety, depression and insomnia; and indices of psychosocial function will all improve, while BZ use will decrease significantly during a twelve-week trial period of substituting…
- Trial name
- NCT01244711
- Testing
- quetiapine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Weill Medical College of Cornell University
Inflammatory Bowel Diseases, Depressive Episode
Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health
This study is a large population-based analysis in the United Kingdom (UK) using routine primary care data to investigate the impacts on quality-of-life outcomes and use of healthcare services in people aged 5 - 25 years…
- Conditions
- Inflammatory Bowel Diseases, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorder
- Trial name
- NCT05206734
- Testing
- No specific intervention
- Where
- United Kingdom
- Volunteers
- 19,469 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Depressive Disorder, Major
A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression
This is a home-based study in adults with depression. People who have been diagnosed with Major Depressive Disorder can participate in the study.
- Trial name
- NCT04423757
- Testing
- BI 1358894
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Boehringer Ingelheim
MDD
Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment
To investigate the efficacy and safety of flexibly dosed adjunctive brexpiprazole treatment in active adults with MDD, 18 to 35 years old, who are experiencing an inadequate selective serotonin reuptake inhibitor (SSRI)/serotonin…
- Trial name
- NCT02013609
- Testing
- Brexpiprazole
- Where
- 24 sites in United States
- Volunteers
- 48 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.